

**Sec/Coat/010/FY 2026-27**

**Date: 15.05.2026**

**The Secretary**  
**BSE Limited**  
New Trading Wing,  
Rotunda Building,  
PJ Tower, Dalal Street,  
Mumbai- 400001  
**Scrip Code: 539046**

**The Manager**  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block "G"  
5<sup>th</sup> floor, Bandra Kurla Complex,  
Bandra East,  
Mumbai- 400051  
**Symbol: MANAKCOAT**

Dear Madam/Sir,

**Sub: Copies of Newspaper Advertisement – Special window for Re-lodgement of Transfer Requests of physical shares**

**Ref.: Regulation 30 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").**

Pursuant to Regulation 30 and 47 of Listing Regulations, please find attached copies of extract of newspaper advertisements published today i.e. Friday, May 15, 2026 in all editions of Business Standard (English) and Ekdin (Bengali) regarding publication of the public notice for the opening of the Special Window for re-lodgement of transfer requests of physical shares.

We are enclosing herewith a copy of each of the aforesaid newspaper publication.

Thanking you,  
Yours faithfully,

**For Manaksia Coated Metals & Industries Limited**

**SHRUTI**  
**AGARWAL**  
Digitally signed by  
SHRUTI AGARWAL  
Date: 2026.05.15  
14:28:47 +05'30'

**Shruti Agarwal**  
Company Secretary & Compliance Officer  
Membership No.: F12124  
Encl: as above



Statutory Body under the Government of India  
Core-5A, 3rd - 5th Floor, India Habitat Centre,  
Lodhi Road, New Delhi - 110003

Financial Results for the Period Ended March 31, 2026 (₹ in lakhs). Table with columns for Particulars, Quarter Ended (31.03.2026, 31.03.2025, 31.12.2025, 9M Ended (31.03.2026, 31.03.2025)), and FY Ended (30.06.2025). Rows include Total Income from operations, Net Profit/(Loss) for the period, Total Comprehensive Income, Equity Share Capital, Reserves, and Earnings Per Share (EPS).

\*Income from operations includes Interest Income on Advances, Bank Deposits and Investments.  
\*Exceptional and/or Extraordinary Items adjusted in the Statement of Profit and Loss in accordance with IndAS Rules/AS Rules, whichever is applicable.  
\*For the quarter/Nine Months ended taken as per audited balance sheet of last financial year

- Notes: a) The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on May 14, 2026 at New Delhi. b) The above is an extract of the detailed format of quarterly/yearly financial results filed with the Stock Exchange(s) under regulation 52 of the SEBI (LODR) Regulations, 2015. c) For the other line items referred in regulation 52(4) of the LODR Regulations, pertinent disclosures have been made to the BSE and NSE and can be accessed on the URL (www.nseindia.com and www.bseindia.com). d) The impact on net profit/loss, total comprehensive income or any other relevant financial items(s) due to change(s) in accounting policies shall be disclosed by means of a footnote. Nil.

Place: New Delhi Date: May 14, 2026



For and on behalf of the Board of Directors  
Sanjay Shukla  
Managing Director

REDINGTON LIMITED

Registered office: Block 3, Plathin, Redington Tower, Inner Ring Road, Saraswathy Nagar West, 4<sup>th</sup> Street, Puzhuvakkam, Chennai - 600 091  
Website: www.redingtongroup.com | Email: investors@redingtongroup.com  
CIN: L52599TN1961PLC028758  
ISIN: IN120224311



Consolidated Financial Results for the Quarter and Year Ended March 31, 2026 (₹ in Crores). Table with columns for Particulars, Quarter Ended (March 31, 2026, March 31, 2025), Year Ended (March 31, 2026, March 31, 2025). Rows include Revenue from operations, Profit before exceptional item and tax, Total comprehensive income, Equity share capital, Reserves and surplus, Securities premium account, Networth, Non-controlling interest, Outstanding Debt, Debt-equity ratio, Earnings per Equity Share.

Notes: 1. Summarized Standalone Financial Results of the Company is as under:

Standalone Financial Results for the Quarter and Year Ended March 31, 2026 (₹ in Crores). Table with columns for Particulars, Quarter Ended (March 31, 2026, March 31, 2025), Year Ended (March 31, 2026, March 31, 2025). Rows include Revenue from operations, Profit before tax, Profit after tax.

2. The above is an extract of the detailed format of Quarterly / Half-Yearly / Annual Financial Results filed with the Stock Exchanges under Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. 3. The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors of Redington Limited at their meeting held on May 13, 2026.



Place: Chennai Date: May 13, 2026  
S V Krishnan  
Finance Director (Whole-time)

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

Q-line Biotech logo and text: Spreading Healthiness! Q-LINE BIOTECH LIMITED THE EQUITY SHARES OF THE COMPANY WILL GET LISTED ON SME PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE EMERGE")

Our Company was originally incorporated as "POCI Services Private Limited" on November 10, 2010 as a Private Limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated November 10, 2010 issued by the Assistant Registrar of Companies, Uttar Pradesh and Uttarakhand bearing CIN U74120UP2010PP0042526. Subsequently, pursuant to a special resolution passed by our shareholders in the Extra-Ordinary General Meeting held on June 12, 2021, the name of our Company was changed to "Q-Line Biotech Private Limited and a fresh certificate of incorporation pursuant to change of name dated July 23, 2021 was issued to our Company by the Registrar of Companies, Kanpur. Further, pursuant to a special resolution passed by our Shareholders in the Extra-Ordinary General Meeting held on February 19, 2025, our Company was converted from a private limited company to public limited company and consequently the name of our Company was changed to "Q-Line Biotech Limited", and a fresh certificate of incorporation dated March 08, 2025 was issued to our Company by the Registrar of Companies, Central Processing Centre, The CIN of the Company is U74120UP2010PP0042526. For further details of incorporation, change of registered office of our Company, please refer to chapter titled "History and Corporate Structure" beginning on page 149 of the Draft Red Herring Prospectus dated September 30, 2025 filed with the NSE Emerge.

Registered Office: 298-281, Transport Nagar, Kanpur Road Adjacent Transport Nagar Metro Station, Lucknow, Uttar Pradesh, India, 226012  
Contact Person: Akhand Pratap Singh, Company Secretary & Compliance Officer.  
Tel No: +91 522-2435570; E-mail: notice@qlinebiotech.com; Website: www.qlinebiotech.com; Corporate Identity Number: U74120UP2010PLC042526.

NOTICE TO INVESTORS ("NOTICE")

INITIAL PUBLIC OFFER OF UPTO 78,53,208 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH ("EQUITY SHARES") OF Q-LINE BIOTECH LIMITED ("OUR COMPANY" OR "Q-LB" OR "THE ISSUER") AT AN ISSUE PRICE OF ₹ 100 PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ 7,85,32,08,000 ("PUBLIC ISSUE").

\*Our Company, in consultation with the Book Running Lead Managers, has undertaken a Pre-IP Placement of 8,00,000 Equity Shares at an issue price of ₹ 343 per Equity Share (including a premium of ₹ 333 per Equity Share) for a cash consideration aggregating to ₹ 27,44,00,000/-, on May 13, 2026. The size of the Fresh Issue has been reduced by the number of equity shares and accordingly, the size of the Fresh Issue is up to 62,53,208 equity shares.

Potential bidders may note the following: Our Company, in consultation with the BRLMs, has undertaken the Pre-IP Placement of 8,00,000 Equity Shares at an issue price of ₹ 343 per Equity Share (including a premium of ₹ 333 per Equity Share) for an amount aggregating to ₹ 27,44,00,000/-, by way of a private placement in accordance with Section 42, 62 of the Companies Act, 2013 read with the Companies (Prospectus and Allotment of Securities) Rules, 2014 and the Companies (Share Capital and Debentures) Rules, 2014, each as amended.

Table with columns: Date of allotment, Number of Equity Shares allotted, Issue price per Equity Share (in INR), Total consideration paid (in INR), Name of the Allottee. Rows include allotments from May 13, 2026 to May 13, 2025.

Accordingly, pursuant to the Pre-IP Placement, the size of the Fresh Issue has been reduced by such number of Equity Shares aggregating up to 8,00,000 equity shares. The abovesmentioned allottee is not, in any manner, connected with the Company, the Promoters, members of the Promoter Group, the Directors, the Key Managerial Personnel, the Group Companies and their respective directors and key managerial personnel to the above Pre-IP placement, shall be subject to Lock-in, in accordance with terms of Regulation 239 of the SEBI (ICDR) Regulations, 2018. Please further note that the Notice does not reflect all the changes that have occurred between the date of filing of the DRHP and the date of this Notice and accordingly, should not include the changes and/or updates that will be included in the Red Herring Prospectus and the Prospectus. The above notice is to be read in conjunction with the DRHP. Further, the company will submitly update the relevant Section in the Red Herring Prospectus and Prospectus to be filed with ROC and the Stock Exchange, to reflect the factual position pursuant to the allotment as on the date of the Red Herring Prospectus and Prospectus.

BOOK RUNNING LEAD MANAGERS TO THE ISSUE REGISTRAR TO THE ISSUE

Logos and contact information for Hem Securities, Share India Capital Services Private Limited, and Purva Sharegistry (India) Private Limited.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For Q-Line Biotech Limited On behalf of the Board of Directors Akhand Pratap Singh Company Secretary and Compliance Officer

RESONANCE SPECIALTIES LIMITED

REGD. OFFICE: 54-D, Kantival Industrial Estate, Chakrapur, Kandiwal (West), MUMBAI 400067  
Website: www.resonancecell.com TEL: 022 6857 2827, 957 106-27A4AACC590012/W. Email: info@resonancecell.com

FINANCIAL RESULTS FOR THE QUARTER ENDED AND YEAR ENDED 31st MARCH, 2026 (₹. In Lakhs). Table with columns for Particulars, Quarter Ended (31st March 2026, 31st March 2025), Year Ended (31st March 2026, 31st March 2025). Rows include Total Income from operations, Net Profit / (Loss) for the period, Total comprehensive income, Equity Share Capital, Audited Balance sheet of the previous year, Earnings per Shares.

Notes: 1. The financial results of the Company have been prepared in accordance with the Companies (Indian Accounting Standards) Rules' 2015 (IND-AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable. 2. The above results have been reviewed by the audit committee and thereafter approved by the Board of Directors in their meeting held on 18th May 2026. 3. The Board has recommended a dividend of ₹ 1/- per share (10% for the financial year 2025-26). 4. In accordance with Ind AS-108 "Operating Segments", the company has only one reportable primary business segment i.e. "Chemical Manufacturing". However, the company has secondary geographical segments which is disclosed in the financial statement as per Ind AS-106. Information about secondary geographical segments as per financial statements

Table with columns: Particulars, April to March 26, April to March 25. Rows include Segment Revenue, India, Outside India, Total.

The segment asset and segment capital expenditure attributable to the segment "Outside India" is less than 10% of the respective total assets and total capital expenditure and therefore not disclosed separately. 5. The Company post notification of new labour code has evaluated its implication on employee benefits and considered the same while making provision for employee benefits including actuarial based gratuity and leave encashment provisions in the financial results. On account of the change the incremental impact in Rs. 10,40 lakhs which is charged to the Profit and Loss Statement. 6. As at 31st March, 2026 the company does not have any subsidiary associate, joint venture entity (JVE). 7. \*The figures of the last quarter for the current year and for the previous year are the balancing figures between the audited figures in respect of the full financial year ended March 31, and unaudited year-to-date figures up to the third quarter ended December 31, which were subjected to limited review. 8. The figures for the previous financial period have been rearranged/reorganized wherever necessary.

By order of the Board For RESONANCE SPECIALTIES LIMITED Sd/- Charchit Jain Whole Time Director DIN: 09344085  
Place: Mumbai, Date: 14<sup>th</sup> May 2026

